Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
Authors
Keywords
Immunotherapy, Immune-related adverse events, Checkpoint inhibitors, Efficacy, Nivolumab, Pembrolizumab, Ipilimumab, Toxicity, Melanoma, Non-small cell lung cancer
Journal
CANCER TREATMENT REVIEWS
Volume 92, Issue -, Pages 102134
Publisher
Elsevier BV
Online
2020-12-03
DOI
10.1016/j.ctrv.2020.102134
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan
- (2020) Masaki Otsuka et al. JOURNAL OF DERMATOLOGY
- Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
- (2020) Teppei Sugano et al. Thoracic Cancer
- Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
- (2020) Kyung Hwan Kim et al. OncoImmunology
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- (2020) Alexander M. M. Eggermont et al. JAMA Oncology
- Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
- (2019) Hamzah Abu-Sbeih et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
- (2019) Hiroki Ishihara et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
- (2019) Roy Elias et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
- (2019) Beung-Chul Ahn et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
- (2019) Alessio Cortellini et al. Clinical Lung Cancer
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
- (2019) Satya Das et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients
- (2019) Pauline Campredon et al. PRESSE MEDICALE
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- The oncological survival and prognosis of individuals receiving PD-1 inhibitor with and without immunologic cutaneous adverse events
- (2019) L. Chan et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
- (2019) Jun Fukihara et al. Clinical Lung Cancer
- Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
- (2018) Yasuhiro Fujisawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
- (2018) Charles Kyung Min Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
- (2018) Daichi Fujimoto et al. LUNG CANCER
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
- (2018) Dwight H. Owen et al. Clinical Lung Cancer
- Biomarkers of response to immune checkpoint blockade in cancer treatment
- (2018) Takeo Fujii et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
- (2018) Naoto Okada et al. CLINICAL THERAPEUTICS
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
- (2018) Biagio Ricciuti et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
- (2018) Alice Indini et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
- (2017) Takeo Fujii et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
- (2016) J Dick et al. Immunotherapy
- Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
- (2016) Yasuhiro Nakamura et al. JOURNAL OF DERMATOLOGY
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
- (2016) Omar Hasan Ali et al. OncoImmunology
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness and Tolerability of Ipilimumab
- (2014) Thomas K. Eigentler et al. JOURNAL OF IMMUNOTHERAPY
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
- (2014) Paolo A Ascierto et al. Journal of Translational Medicine
- Ipilimumab in advanced melanoma
- (2012) Alberto Farolfi et al. MELANOMA RESEARCH
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started